Glaukos Corporation $GKOS Shares Acquired by Allspring Global Investments Holdings LLC

Allspring Global Investments Holdings LLC increased its position in Glaukos Corporation (NYSE:GKOS) by 32.8% in the fourth quarter, Holdings Channel reports. The firm owned 355,279 shares of the medical instruments supplier’s stock after purchasing an additional 87,781 shares during the quarter. Allspring Global Investments Holdings LLC’s holdings in Glaukos were worth $39,336,000 as of its most recent SEC filing.

Other hedge funds also recently made changes to their positions in the company. UMB Bank n.a. increased its holdings in shares of Glaukos by 102.6% in the 3rd quarter. UMB Bank n.a. now owns 312 shares of the medical instruments supplier’s stock valued at $25,000 after acquiring an additional 158 shares during the last quarter. REAP Financial Group LLC bought a new position in shares of Glaukos in the 3rd quarter worth about $40,000. Smartleaf Asset Management LLC boosted its holdings in shares of Glaukos by 16.2% in the 2nd quarter. Smartleaf Asset Management LLC now owns 973 shares of the medical instruments supplier’s stock valued at $99,000 after buying an additional 136 shares during the period. SBI Securities Co. Ltd. grew its position in shares of Glaukos by 42.9% during the 3rd quarter. SBI Securities Co. Ltd. now owns 1,205 shares of the medical instruments supplier’s stock valued at $98,000 after buying an additional 362 shares during the last quarter. Finally, State of Wyoming grew its position in shares of Glaukos by 13.1% during the 3rd quarter. State of Wyoming now owns 1,723 shares of the medical instruments supplier’s stock valued at $141,000 after buying an additional 199 shares during the last quarter. Institutional investors and hedge funds own 99.04% of the company’s stock.

Glaukos Stock Performance

Shares of NYSE GKOS opened at $112.68 on Friday. Glaukos Corporation has a 1 year low of $73.16 and a 1 year high of $130.23. The firm has a market cap of $6.54 billion, a P/E ratio of -34.57 and a beta of 0.78. The stock has a fifty day moving average price of $111.82 and a two-hundred day moving average price of $102.51. The company has a debt-to-equity ratio of 0.10, a quick ratio of 4.06 and a current ratio of 4.69.

Glaukos (NYSE:GKOS) last posted its quarterly earnings data on Tuesday, February 17th. The medical instruments supplier reported ($0.28) EPS for the quarter, missing analysts’ consensus estimates of ($0.22) by ($0.06). The firm had revenue of $143.12 million during the quarter, compared to the consensus estimate of $132.16 million. Glaukos had a negative return on equity of 7.00% and a negative net margin of 36.99%.The firm’s quarterly revenue was up 35.6% on a year-over-year basis. During the same period in the prior year, the firm posted ($0.40) EPS. Research analysts forecast that Glaukos Corporation will post -1.08 EPS for the current fiscal year.

Insider Buying and Selling at Glaukos

In other Glaukos news, CFO Alex R. Thurman sold 2,511 shares of the company’s stock in a transaction on Wednesday, March 25th. The stock was sold at an average price of $106.46, for a total value of $267,321.06. Following the transaction, the chief financial officer owned 41,967 shares of the company’s stock, valued at approximately $4,467,806.82. This represents a 5.65% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CEO Thomas William Burns sold 186,945 shares of the firm’s stock in a transaction on Friday, January 16th. The stock was sold at an average price of $115.00, for a total value of $21,498,675.00. Following the sale, the chief executive officer directly owned 153,775 shares of the company’s stock, valued at approximately $17,684,125. This represents a 54.87% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Over the last quarter, insiders sold 324,657 shares of company stock valued at $37,692,269. Corporate insiders own 5.80% of the company’s stock.

Analyst Ratings Changes

Several research firms have recently commented on GKOS. Needham & Company LLC upped their target price on Glaukos from $125.00 to $127.00 and gave the company a “buy” rating in a report on Wednesday, February 18th. Citigroup upped their price objective on Glaukos from $113.00 to $125.00 and gave the stock a “buy” rating in a research note on Thursday, December 11th. Stephens raised their target price on Glaukos from $115.00 to $145.00 and gave the company an “overweight” rating in a research note on Friday, January 2nd. Wells Fargo & Company increased their price objective on shares of Glaukos from $122.00 to $135.00 and gave the stock an “overweight” rating in a report on Wednesday, February 18th. Finally, Stifel Nicolaus lifted their price objective on shares of Glaukos from $115.00 to $160.00 and gave the company a “buy” rating in a research report on Thursday, January 22nd. One research analyst has rated the stock with a Strong Buy rating, twelve have assigned a Buy rating, one has assigned a Hold rating and two have given a Sell rating to the company’s stock. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus target price of $133.69.

About Glaukos

Glaukos Corporation is a medical technology company specializing in the development, manufacturing and commercialization of innovative therapies for patients with glaucoma and other chronic eye diseases. The company’s core offerings focus on micro-invasive glaucoma surgery (MIGS), designed to reduce intraocular pressure and manage glaucoma more safely and effectively than traditional surgical approaches. Glaukos’s flagship products include the iStent, iStent inject and iStent infinite trabecular micro-bypass stents, which are implanted during cataract surgery to improve aqueous outflow and help control eye pressure.

Beyond its MIGS portfolio, Glaukos has expanded into sustained drug-delivery solutions.